We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
CytRx's lead drug candidate, arimoclomol, has been granted orphan medicinal product status for the treatment of amyotrophic lateral sclerosis (ALS) by the European Commission.
By combining four proteins of Staphylococcus aureus that individually generated the strongest immune response in mice, scientists have created a vaccine that significantly protects the animals from diverse strains of the bacterium that cause disease in humans.
Berlex Oncology has announced that a national clinical study is under way investigating a new approach to treating follicular B-cell lymphoma, a sub-type of non-Hodgkin's lymphoma (NHL).
Regeneron Pharmaceuticals has announced positive data from a Phase III clinical program designed to provide two separate demonstrations of efficacy for the investigational drug Interleukin-1 (IL-1) Trap within a single group of patients suffering from a rare chronic disease known as CIAS1-related autoinflammatory periodic syndromes (CAPS).
Pfizer has provided an update on the preliminary results of its torcetrapib/atorvastatin clinical trials in connection with the release of an American Heart Association abstract of a Phase III study in patients with heterozygous familial hypercholesterolemia (HeFH) that shows the drug significantly raising good (HDL) cholesterol (56 percent) and lowering bad (LDL) cholesterol (27 percent) compared with patients taking atorvastatin alone.